ChartMill assigns a Buy % Consensus number of 47% to ADGI. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-05-17 | Morgan Stanley | Maintains | Underweight |
| 2022-01-06 | Morgan Stanley | Downgrade | Equal-Weight -> Underweight |
| 2021-12-22 | Jefferies | Downgrade | Buy -> Hold |
| 2021-12-15 | Guggenheim | Downgrade | Buy -> Neutral |
| 2021-12-15 | Stifel | Downgrade | Buy -> Hold |
| 2021-12-15 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2021-11-29 | Morgan Stanley | Upgrade | Equal-Weight -> Overweight |
| 2021-08-31 | Guggenheim | Initiate | Buy |
| 2021-08-31 | Stifel | Initiate | Buy |
| 2021-08-31 | Morgan Stanley | Initiate | Equal-Weight |
| 2021-08-31 | Jefferies | Initiate | Buy |
9 analysts have analysed ADGI and the average price target is 3.91 USD. This implies a price decrease of -15.73% is expected in the next year compared to the current price of 4.64.
The consensus rating for ADAGIO THERAPEUTICS INC (ADGI) is 46.6667 / 100 . This indicates that analysts generally have a neutral outlook on the stock.
The number of analysts covering ADAGIO THERAPEUTICS INC (ADGI) is 9.